Genentech bldg 32

ORIC Pharmaceuticals, Inc. is a South San Francisco-based biopharmaceutical company dedicated to improving the lives of cancer patients by targeting resistance mechanisms. With a focus on discovering, developing, and commercializing innovative therapies, ORIC aims to enhance the efficacy and duration of existing cancer treatments, addressing the persistent challenges of therapeutic resistance and relapse. Driven by a shared purpose, ORIC's resistance platform concentrates on three key areas: innate resistance, acquired resistance, and bypass resistance. By enrolling patients in phase 1 clinical trials for ORIC-533 in multiple myeloma, ORIC-114 in EGFR HER2 cancers, and ORIC-944 in prostate cancer, the company is actively advancing its mission to combat treatment-resistant cancers. With a collaborative and open culture, ORIC empowers its team to conduct cutting-edge work in the field of oncology, striving to make a significant impact on the lives of cancer patients.Generated from the website